T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation for a Patient With Tcf3-Hlf-Positive Acute Lymphoblastic Leukemia Extramedullary Relapse After Unrelated Bone Marrow Transplantation.
Male
Humans
Child, Preschool
Bone Marrow Transplantation
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ therapy
T-Lymphocytes
Hematopoietic Stem Cell Transplantation
/ methods
Recurrence
Acute Disease
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Receptors, Antigen, T-Cell
Retrospective Studies
Unrelated Donors
Basic Helix-Loop-Helix Transcription Factors
Oncogene Proteins, Fusion
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
20
01
2022
accepted:
18
07
2022
pubmed:
27
9
2022
medline:
28
3
2023
entrez:
26
9
2022
Statut:
ppublish
Résumé
TCF3-HLF-positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has an extremely poor prognosis. A 2-year-old boy with TCF3-HLF-positive BCP-ALL had an isolated extramedullary relapse in multiple bones after allogeneic hematopoietic stem cells transplantation (HSCT) from a human leukocyte antigen-matched unrelated donor. In this study, he received a T-cell-replete haploidentical HSCT (TCR-haplo-HSCT) from his father when in nonremission state, which resulted in a sustained complete remission for over 3 years. Immune therapies for patients with an extramedullary relapse of TCF3-HLF-positive BCP-ALL have been attempted; however, long-term efficacies of these therapies remain unknown. Our TCR-haplo-HSCT may be an effective therapeutic option for such patients.
Identifiants
pubmed: 36162014
doi: 10.1097/MPH.0000000000002555
pii: 00043426-202304000-00035
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
TCF3 protein, human
0
Basic Helix-Loop-Helix Transcription Factors
0
TCF3-HLF fusion protein, human
0
Oncogene Proteins, Fusion
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e419-e422Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059–1064.
Raimondi SC, Privitera E, Williams DL, et al. New recurring chromosomal translocations in childhood acute lymphoblastic leukemia. Blood. 1991;77:2016–2022.
Minson KA, Prasad P, Vear S, et al. t(17;19) in children with acute lymphocytic leukemia: a report of 3 cases and a review of the literature. Case Rep Hematol. 2013;2013:563291.
Inukai T, Hirose K, Inaba T, et al. Hypercalcemia in childhood acute lymphoblastic leukemia: frequent implication of parathyroid hormone-related peptide and E2A-HLF from translocation 17;19. Leukemia. 2007;21:288–296.
Eckert C, Hagedorn N, Sramkova L, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia. 2015;29:1648–1655.
Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009;23:2259–2264.
Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet. 2010;376:2009–2017.
Andersson BS, Valdez BC, de Lima M, et al. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011;17:893–900.
Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015;47:1020–1029.
Mouttet B, Vinti L, Ancliff P, et al. Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation. Haematologica. 2019;104:e244–e247.
Wu S, Lu J, Su D, et al. The advantage of chimeric antigen receptor T cell therapy inpediatric acute lymphoblastic leukemia with E2A-HLF fusion gene positivity: a case series. Transl Pediatr. 2021;10:686–691.
Wang T, Wan X, Yang F, et al. Successful treatment of TCF3-HLF-positive childhood B-ALL with chimeric antigen receptor T-cell therapy. Clin Lymphoma Myeloma Leuk. 2021;21:386–392.
Hirai M, Yagasaki H, Fujimura J, et al. Successful preemptive donor lymphocyte infusions from a haploidentical donor in a boy with E2A-HLF-positive ALL. Leuk Lymphoma. 2018;59:746–748.
Zhang X, Inukai T, Hirose K, et al. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors. Leukemia. 2012;26:2483–2493.
Sano H, Mochizuki K, Kobayashi S, et al. T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia. Int J Hematol. 2018;108:76–84.
Kobayashi S, Ito M, Sano H, et al. T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia. Transfus Med. 2014;24:305–310.
Mochizuki K, Kikuta A, Ito M, et al. Feasibility of tacrolimus, methotrexate, and prednisolone as a graft-versus-host disease prophylaxis in non-T-cell-depleted haploidentical hematopoietic stem cell transplantation for children. Clin Transplant. 2011;25:892–897.
Takahashi N, Mochizuki K, Sano H, et al. Decline of serum albumin precedes severe acute GVHD after haploidentical HSCT. Pediatr Int. 2021;63:1048–1054.
Sano H, Mochizuki K, Kobayashi S, et al. Effectiveness of T-Cell replete haploidentical hematopoietic stem cell transplantation for refractory/relapsed B cell acute lymphoblastic leukemia in children and adolesents. Front Prediatr. 2021;9:743294.